AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 261 min read$RCKT

Shah Gaurav sold $172K of RCKT

Shah Gaurav (CEO) sold 55,684 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.09 ($0.17M total) on 2026-05-21.

Original reporting
SEC EDGAR · Shah Gaurav
Published May 26, 2026, 11:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 11:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Neutral
medium confidence
Mentioned
$RCKT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The disclosure may slightly weigh on sentiment for RCKT traders, but it does not introduce new operational, clinical, or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

No context on prior sales cadence, total insider ownership trend, or whether the sale was part of broader personal financial planning.

Relevance 6/10Timing: Immediate (same-day read-through for sentiment), but not a catalyst for fundamentals.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Rocket Pharmaceuticals (RCKT).

Company-level read

Ticker impact

$RCKTNeutralMedium confidence
Context

Rocket Pharmaceuticals CEO Shah Gaurav sold 55,684 shares in an open-market transaction reported on SEC Form 4.

Expected impact

Likely limited, short-lived impact unless follow-on selling accelerates or coincides with other negative news.

Evidence & confidence

This is a routine Form 4 disclosure (no 10b5-1 plan stated) with a modest dollar amount relative to typical market moves; without accompanying company-specific news, directional conviction is low.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide regulatory/clinical developments.

Regional

None indicated; filing is US-based and company-specific.

Global

Low—no international deal, trial, or regulatory action referenced.

Counterpoint

What could challenge this read

The sale could be liquidity-driven (taxes/diversification) and does not necessarily reflect negative expectations.

Key entities

  • issuer
    Rocket Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale by CEO Shah Gaurav.

  • insider
    Shah Gaurav

    CEO who sold 55,684 shares at $3.0860/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

OCT 8
$RCKTMed

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, citing encouraging clinical updates on its gene therapy candidate RP-A501. The company remains unprofitable with no revenue, but its market cap of $284M reflects growth expectations. RCKT's GF Score is 35/100, showing mixed fundamentals. Insiders have sold shares, while some institutional investors hold positions.

gurufocus.com5 min
OCT 8
$RCKTHigh

Why is Rocket Pharmaceuticals stock up 3% today?

Rocket Pharmaceuticals (RCKT) rose 2.8% after Goldman Sachs upgraded it to Neutral with a $4.00 price target, citing positive clinical data for RP-A501. Other analysts maintained bullish ratings, while some lowered targets due to long timelines. The company secured a $150M credit facility. The move was company-specific, as broader markets were down.

investing.com2 min
OCT 8
$RCKTMedAI 8/10

Rocket Pharmaceuticals bags $150 million as it pushes pivotal Danon disease study

Rocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.

indianpharmapost.com2 min